Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Sales | 31,073 | 0 | 0 | 0 | 0 |
Gross Profit | 31,073 | N/A | N/A | N/A | N/A |
Operating Expenses | 132,752 | 93,111 | 87,582 | 52,602 | 108,150 |
Operating Income | -101,679 | -93,111 | -87,582 | -52,602 | -108,150 |
Interest Expense | 18,945 | 14,907 | 2,583 | 0 | 0 |
Other Income | 15,254 | 2,017 | 167 | 1,616 | 5,342 |
Pre-tax Income | -105,370 | -106,001 | -89,998 | -50,986 | -102,808 |
Net Income Continuous | -105,370 | -106,001 | -89,998 | -50,986 | -102,808 |
Net Income | $-105,370 | $-106,001 | $-89,998 | $-50,986 | $-102,808 |
EPS Basic Total Ops | -0.99 | -1.21 | -1.27 | -0.74 | -1.53 |
EPS Basic Continuous Ops | -0.99 | -1.21 | -1.27 | -0.74 | -1.53 |
EPS Diluted Total Ops | -0.99 | -1.21 | -1.27 | -0.74 | -1.53 |
EPS Diluted Continuous Ops | -0.99 | -1.21 | -1.27 | -0.74 | -1.53 |
EPS Diluted Before Non-Recurring Items | -0.99 | -1.21 | -1.27 | -0.74 | -1.46 |
EBITDA(a) | $-108,862 | $-93,360 | $-86,276 | $-52,074 | $-109,815 |